C. Sessa

1.6k total citations · 1 hit paper
24 papers, 1.1k citations indexed

About

C. Sessa is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, C. Sessa has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Reproductive Medicine and 6 papers in Molecular Biology. Recurrent topics in C. Sessa's work include Ovarian cancer diagnosis and treatment (8 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). C. Sessa is often cited by papers focused on Ovarian cancer diagnosis and treatment (8 papers), Cancer Treatment and Pharmacology (5 papers) and Lung Cancer Research Studies (5 papers). C. Sessa collaborates with scholars based in Switzerland, Italy and United Kingdom. C. Sessa's co-authors include J. Wanders, H. Franklin, Stuart Kaye, Nicoletta Colombo, Jonathan A. Ledermann, Aarón Sulkes, Joan A. Smyth, J. B. Vermorken, Jaap Verweij and M. Castiglione and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

C. Sessa

24 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

2019 259 citations Nicoletta Colombo, C. Sessa et al. International Journal of Gynecological Cancer profile →

Peers

C. Sessa

ONCOL

PRM

SURGE

Susan Schumer United States

Anne‐Claire Hardy‐Bessard France

Aránzazu Manzano Spain

Lawrence R. Nycum United States

Steven E. Vogl United States

Catherine Shannon Australia

J. Carmichael United Kingdom

Matthew Tan United States

Eizo Kimura Japan

R. Largillier France

Susan Schumer United States

C. Sessa

422 ×0.6

ONCOL

425 ×1.0

338 ×1.1

PRM

517 ×1.9

129 ×0.5

SURGE

Citations per year, relative to C. Sessa C. Sessa (= 1×) peers Susan Schumer

Countries citing papers authored by C. Sessa

Since Specialization

Citations

This map shows the geographic impact of C. Sessa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Sessa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Sessa more than expected).

Fields of papers citing papers by C. Sessa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Sessa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Sessa. The network helps show where C. Sessa may publish in the future.

Co-authorship network of co-authors of C. Sessa

This figure shows the co-authorship network connecting the top 25 collaborators of C. Sessa. A scholar is included among the top collaborators of C. Sessa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Sessa. C. Sessa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sessa, C., Javier Cortés, Pierfranco Conté, et al.. (2021). The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective. ESMO Open. 7(1). 100339–100339. 25 indexed citations

Colombo, Nicoletta, C. Sessa, Andreas du Bois, et al.. (2019). ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecological Cancer. 29(4). 728–760. 259 indexed citations breakdown →

Fasolo, Angelica, Anastasios Stathis, C. Sessa, et al.. (2018). Abstract CT014: A large phase I study of TAS-114 in combination with S-1 in patients with advanced solid tumors. Cancer Research. 78(13_Supplement). CT014–CT014. 4 indexed citations

Ledermann, Jonathan A., C. Sessa, & N. Colombo. (2016). appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies). Annals of Oncology. 27(suppl 5). v145–v145. 6 indexed citations

Mateo, Joaquı́n, Víctor Moreno, Avinash Gupta, et al.. (2016). An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. Targeted Oncology. 11(3). 401–415. 104 indexed citations

Joerger, Markus, Dagmar Hess, Angelo Delmonte, et al.. (2015). Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). British Journal of Clinical Pharmacology. 80(1). 128–138. 10 indexed citations

Joerger, Markus, Dagmar Hess, Angelo Delmonte, et al.. (2015). Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. Investigational New Drugs. 33(2). 472–479. 9 indexed citations

Driessen, Christoph, Dagmar Hess, Thomas Pabst, et al.. (2012). SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.. Blood. 120(21). 2956–2956. 1 indexed citations

Sessa, C.. (2011). Update on PARP1 inhibitors in ovarian cancer. Annals of Oncology. 22. viii72–viii76. 29 indexed citations

10.

Achtari, Chahin, et al.. (2011). Bevacizumab in the primary treatment of epithelial ovarian cancer – some comments on the latest results. Zurich Open Repository and Archive (University of Zurich). 35(1). 35–38. 1 indexed citations

11.

Colombo, Nicoletta, Michele Peiretti, Gabriella Parma, et al.. (2010). Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 21. v23–v30. 146 indexed citations

12.

Hess, Dagmar, Angelo Delmonte, Elisa Gallerani, et al.. (2009). Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data. Journal of Clinical Oncology. 27(15_suppl). 2570–2570. 3 indexed citations

13.

Zatloukal, Petr, Radj Gervais, Johan Vansteenkiste, et al.. (2008). Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(8). 894–901. 22 indexed citations

14.

Bourbouloux, Emmanuelle, et al.. (2006). Phase I study of intravenous (IV) milataxel in adult patients with advanced malignant tumors. Journal of Clinical Oncology. 24(18_suppl). 2037–2037. 3 indexed citations

15.

Roth, A, Rudolf Maibach, Nicola Fazio, et al.. (2004). 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial. Annals of Oncology. 15(5). 759–764. 36 indexed citations

16.

Pas, Tommaso De, Filippo de Braud, Romano Danesi, et al.. (2000). Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. Annals of Oncology. 11(7). 821–827. 25 indexed citations

17.

Hansen, Steen Werner, Malgorzata Tuxen, & C. Sessa. (1999). Gemcitabine in the treatment of ovarian cancer. Annals of Oncology. 10. S51–S53. 4 indexed citations

18.

Smyth, J F, I E Smith, C. Sessa, et al.. (1994). Activity of docetaxel (Taxotere) in small cell lung cancer. European Journal of Cancer. 30(8). 1058–1060. 105 indexed citations

19.

Sulkes, Aarón, Joan A. Smyth, C. Sessa, et al.. (1994). Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. British Journal of Cancer. 70(2). 380–383. 198 indexed citations

20.

Goldhirsch, Aron, Richard Greiner, E. Dreher, et al.. (1988). Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy. Cancer. 62(1). 40–47. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact